2024
Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review
Le G, Wong S, Badulescu S, Au H, Di Vincenzo J, Gill H, Phan L, Rhee T, Ho R, Teopiz K, Kwan A, Rosenblat J, Mansur R, McIntyre R. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review. Journal Of Affective Disorders 2024, 355: 342-354. PMID: 38570038, DOI: 10.1016/j.jad.2024.03.165.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionLysergic acid diethylamideSerotonergic psychedelicsDepressive disorderHealthy controlsTheta powerHealthy volunteersBiomarkers predictive of responseGamma-band powerAssociated with increased theta powerSystematic reviewDissociative classDose of treatmentPredictive of responseClasses of agentsMood disordersBeta and delta bandsMDDAcid diethylamideMechanism of actionBiomarkers predictiveDepressionPatient populationModel of network connectivityResearch vistas
2023
Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol
Kitay B, Murphy E, Macaluso M, Corlett P, Hershenberg R, Joormann J, Martinez-Kaigi V, Nikayin S, Rhee T, Sanacora G, Shelton R, Thase M, Wilkinson S. Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol. Psychiatry Research 2023, 330: 115585. PMID: 37935086, DOI: 10.1016/j.psychres.2023.115585.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyMajor depressionSuicidal ideationRelapse preventionBehavioral therapyStudy protocolHigh riskClinical trial study protocolLong-term treatment approachKey secondary outcomesTrial study protocolHigh relapse rateHigh-risk populationSignificant suicidal ideationHospital dischargeSecondary outcomesPrimary outcomeRelapse rateFeasibility trialEsketamineTreatment approachesPatientsSuicide attemptsTherapySupplemental indicationsA narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia
Wu J, Kwan A, Rhee T, Ho R, d’Andrea G, Martinotti G, Teopiz K, Ceban F, McIntyre R. A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia. Expert Review Of Clinical Pharmacology 2023, 16: 1085-1092. PMID: 37864424, DOI: 10.1080/17512433.2023.2274538.Peer-Reviewed Original ResearchConceptsDepressive symptomsSide effectsBipolar disorderRecent phase 2 trialsPhase 2 trialPhase 1 studyTreatment-resistant schizophreniaExtrapyramidal side effectsD2 receptor bindingReceptor-mediated effectsTreatment of schizophreniaMajor depressive disorderImproved treatment strategiesBipolar disorder IDevelopment of SEPAntidepressant effectsDepressive disorderTreatment strategiesPharmacological profileLow dosesNarrative reviewDisorder ISymptomsAmisulprideReceptor bindingDextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials
Akbar D, Rhee T, Ceban F, Ho R, Teopiz K, Cao B, Subramaniapillai M, Kwan A, Rosenblat J, McIntyre R. Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials. CNS Drugs 2023, 37: 867-881. PMID: 37792265, DOI: 10.1007/s40263-023-01032-5.Peer-Reviewed Original ResearchConceptsMajor depressive disorderPathophysiology of MDDSystematic reviewMontgomery-Åsberg Depression Rating ScaleNMDA receptor antagonist dextromethorphanTransient adverse eventsRisk of biasDepression Rating ScaleMonoamine-based antidepressantsTreatment of depressionBackgroundA significant proportionPlacebo control groupCombination of dextromethorphanMechanism of actionConclusionCurrent evidenceClinical remissionAdverse eventsCochrane riskBias toolDatabase inceptionTreatment optionsScore reductionClinical trialsDepressive disorderActive control groupExploring the potential of a bridge therapy: Synergistic approach integrating intravenous ketamine and intranasal esketamine for treatment‐resistant depression
d'Andrea G, Pettorruso M, Rhee T, Di Lorenzo G, McIntyre R, Martinotti G. Exploring the potential of a bridge therapy: Synergistic approach integrating intravenous ketamine and intranasal esketamine for treatment‐resistant depression. Acta Psychiatrica Scandinavica 2023, 148: 385-387. PMID: 37688284, DOI: 10.1111/acps.13605.Peer-Reviewed Original ResearchGlucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review
Cooper D, Ramachandra R, Ceban F, Di Vincenzo J, Rhee T, Mansur R, Teopiz K, Gill H, Ho R, Cao B, Lui L, Jawad M, Arsenault J, Le G, Ramachandra D, Guo Z, McIntyre R. Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review. Journal Of Psychiatric Research 2023, 164: 80-89. PMID: 37331261, DOI: 10.1016/j.jpsychires.2023.05.041.Peer-Reviewed Original ResearchConceptsGLP-1 receptor agonistsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsIncident depressionDiabetes mellitusReceptor agonistType 2 diabetes mellitusRetrospective observational studyPubMed/MEDLINEEnglish-language articlesHigh interstudy heterogeneityGoogle Scholar databasesPaucity of literatureGlycemic controlNeuroprotective effectsAntidepressant propertiesNeuroprotective potentialInterstudy heterogeneityObservational studyPatientsSystematic reviewAgonistsMellitusScholar databasesProtective factorsEffects of Electroconvulsive Therapy on Functional Outcomes Among Medicare Patients With Comorbid Depression and Dementia: A Nationwide 1-Year Follow-Up Study.
Wilkinson S, Sint K, Forester B, Rhee T. Effects of Electroconvulsive Therapy on Functional Outcomes Among Medicare Patients With Comorbid Depression and Dementia: A Nationwide 1-Year Follow-Up Study. The Journal Of Clinical Psychiatry 2023, 84 PMID: 36700843, DOI: 10.4088/jcp.22m14583.Peer-Reviewed Original ResearchConceptsElectroconvulsive therapyFunctional outcomeComorbid depressionPrincipal psychiatric diagnosisRandomized clinical trialsECT cohortECT patientsComparable cohortsSafe treatmentClinical trialsMedicare patientsCurrent treatmentFunctional declineLimited efficacyPropensity score methodsPsychiatric disordersSummary scoresPsychiatric diagnosisLarger sample sizeMultivariate analysisPsychological symptomsDementiaPatientsOlder adultsCohort
2022
Biomarkers of ketamine's antidepressant effect: An umbrella review
Meshkat S, Ho R, Cao B, Teopiz K, Rosenblat J, Rhee T, Di Vincenzo J, Ceban F, Jawad M, McIntyre R. Biomarkers of ketamine's antidepressant effect: An umbrella review. Journal Of Affective Disorders 2022, 323: 598-606. PMID: 36521662, DOI: 10.1016/j.jad.2022.12.021.Peer-Reviewed Original ResearchConceptsKetamine's antidepressant effectsAntidepressant effectsUmbrella reviewMajor depressive disorder (MDD) pathogenesisRapid acting antidepressant (RAAD) effectsMechanistically relevant biomarkersPotential peripheral biomarkerTreatment-resistant patientsAnti-inflammatory effectsNMDA receptor antagonistReal-world populationTreatment response predictionInflammatory markersPeripheral biomarkersKetamine actionReceptor antagonistSymptom deteriorationClinical utilityNeuroimaging biomarkersDisorder pathogenesisSynaptic plasticityCingulate cortexSystematic reviewKetamineFunctional connectivityKetamine use in pediatric depression: A systematic review
Meshkat S, Rosenblat J, Ho R, Rhee T, Cao B, Ceban F, Danayan K, Chisamore N, Vincenzo J, McIntyre R. Ketamine use in pediatric depression: A systematic review. Psychiatry Research 2022, 317: 114911. PMID: 37732856, DOI: 10.1016/j.psychres.2022.114911.Peer-Reviewed Original ResearchConceptsSafety of ketamineRandomized clinical trialsPediatric depressionIntravenous ketamineNon-competitive N-methyl-D-aspartate (NMDA) receptor antagonistN-methyl-D-aspartate receptor antagonistSystematic reviewOpen-label trialSevere adverse eventsCommon psychiatric disordersDifferent administration modalitiesAdverse eventsAntidepressant effectsSignificant morbidityMean ageCase reportReceptor antagonistClinical trialsAdministration modalitiesDepressive symptomsPsychiatric disordersKetamine useElectronic databasesLarger sample sizeKetamineEvaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting
Nikayin S, Rhee TG, Cunningham ME, de Fontnouvelle CA, Ostroff RB, Sanacora G, Wilkinson ST. Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting. JAMA Psychiatry 2022, 79: 736-738. PMID: 35544190, PMCID: PMC9096687, DOI: 10.1001/jamapsychiatry.2022.1074.Peer-Reviewed Original Research
2021
Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial
Wilkinson ST, Rhee TG, Joormann J, Webler R, Ortiz Lopez M, Kitay B, Fasula M, Elder C, Fenton L, Sanacora G. Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial. Psychotherapy And Psychosomatics 2021, 90: 318-327. PMID: 34186531, DOI: 10.1159/000517074.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionCognitive behavioral therapyAntidepressant effectsClinical trialsMontgomery-Asberg Depression Rating ScaleBehavioral therapyGreater sustained improvementsRapid-acting antidepressantsSubset of patientsDepression Rating ScaleTime interaction effectsEffect sizeKetamine respondersClinical responseIntravenous ketamineIntravenous infusionQuick InventoryOngoing treatmentSustained improvementCBT groupTreatment approachesLong-term exposureLarge effect sizesDepressive symptomatologyKetamine
2020
Prevalence of Treatment for Depression Among US Adults Who Screen Positive for Depression, 2007-2016
Rhee TG, Wilkinson ST, Steffens DC, Rosenheck RA, Olfson M. Prevalence of Treatment for Depression Among US Adults Who Screen Positive for Depression, 2007-2016. JAMA Psychiatry 2020, 77: 1193-1195. PMID: 32609306, PMCID: PMC7330829, DOI: 10.1001/jamapsychiatry.2020.1818.Peer-Reviewed Original Research
2018
Effects of the 2009 USPSTF Depression Screening Recommendation on Diagnosing and Treating Mental Health Conditions in Older Adults: A Difference-in-Differences Analysis
Rhee TG, Capistrant BD, Schommer JC, Hadsall RS, Uden DL. Effects of the 2009 USPSTF Depression Screening Recommendation on Diagnosing and Treating Mental Health Conditions in Older Adults: A Difference-in-Differences Analysis. Journal Of Managed Care & Specialty Pharmacy 2018, 24: 10.18553/jmcp.2018.24.8.769. PMID: 30058984, PMCID: PMC6084471, DOI: 10.18553/jmcp.2018.24.8.769.Peer-Reviewed Original ResearchConceptsNational Ambulatory Medical Care SurveyU.S. Preventive Services Task ForceMental health conditionsOutpatient primary care visitsPrimary care visitsCare visitsScreening recommendationsHealth conditionsOlder adultsAmbulatory Medical Care SurveyPrimary care physician practice patternsRate of underdiagnosisPrimary care settingMental health diagnosesPhysician practice patternsNational InstituteU.S. older adultsDifferential effectsCommon mental conditionsEffectiveness of depressionAntidepressant prescriptionsScreening statusRecommendation statementCare SurveyPractice patterns
2017
Effects of depression screening on diagnosing and treating mood disorders among older adults in office-based primary care outpatient settings: An instrumental variable analysis
Rhee TG, Capistrant BD, Schommer JC, Hadsall RS, Uden DL. Effects of depression screening on diagnosing and treating mood disorders among older adults in office-based primary care outpatient settings: An instrumental variable analysis. Preventive Medicine 2017, 100: 101-111. PMID: 28414065, DOI: 10.1016/j.ypmed.2017.04.015.Peer-Reviewed Original ResearchConceptsNational Ambulatory Medical Care SurveyEffect of depressionAntidepressant prescriptionsDepression screeningOlder adultsMood disordersCross-sectional population-based studyOutpatient primary care settingPrimary care outpatient settingPrimary care outpatient visitsAmbulatory Medical Care SurveyPrimary care visitsOlder adult patientsPopulation-based studyPrimary care physiciansPrimary care settingOlder adults age 65Mood disorder diagnosisOutcomes of interestAdults age 65Effectiveness of depressionAdult patientsCare visitsCare physiciansOutpatient visits
2016
Is Health Literacy Associated With Depressive Symptoms Among Korean Adults? Implications for Mental Health Nursing
Rhee TG, Lee HY, Kim NK, Han G, Lee J, Kim K. Is Health Literacy Associated With Depressive Symptoms Among Korean Adults? Implications for Mental Health Nursing. Perspectives In Psychiatric Care 2016, 53: 234-242. PMID: 27198862, DOI: 10.1111/ppc.12162.Peer-Reviewed Original ResearchMeSH KeywordsAdultDepressionFemaleHealth LiteracyHumansMaleMiddle AgedPsychiatric NursingRepublic of KoreaConceptsHealth literacyDepressive symptomsKorean adultsCommunity-dwelling Korean adultsHealth promotion interventionsRelevant treatment optionsRelevant risk factorsMental health nursingMultivariate regression analysisTreatment optionsRisk factorsPromotion interventionsHealth nursingSymptomsQuota sampling strategyRegression analysisAdultsDepressionLow levelsHigh levelsAdults' understandingImportant role